CN1459316A - Plant substrates - Google Patents
Plant substrates Download PDFInfo
- Publication number
- CN1459316A CN1459316A CN 02120138 CN02120138A CN1459316A CN 1459316 A CN1459316 A CN 1459316A CN 02120138 CN02120138 CN 02120138 CN 02120138 A CN02120138 A CN 02120138A CN 1459316 A CN1459316 A CN 1459316A
- Authority
- CN
- China
- Prior art keywords
- plant
- oil
- substrate
- edible
- juice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000758 substrate Substances 0.000 title claims description 133
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 55
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 41
- 235000018927 edible plant Nutrition 0.000 claims abstract description 11
- 241000196324 Embryophyta Species 0.000 claims description 145
- 239000003921 oil Substances 0.000 claims description 43
- 235000019198 oils Nutrition 0.000 claims description 43
- 239000000835 fiber Substances 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 230000003204 osmotic effect Effects 0.000 claims description 24
- 239000012530 fluid Substances 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 16
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 14
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 14
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 14
- 239000005642 Oleic acid Substances 0.000 claims description 14
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 14
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 235000013311 vegetables Nutrition 0.000 claims description 13
- 102000004895 Lipoproteins Human genes 0.000 claims description 12
- 108090001030 Lipoproteins Proteins 0.000 claims description 12
- 239000010775 animal oil Substances 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 12
- 239000008158 vegetable oil Substances 0.000 claims description 12
- 239000000084 colloidal system Substances 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 241000219357 Cactaceae Species 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 6
- 241000272525 Anas platyrhynchos Species 0.000 claims description 6
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims description 6
- 235000006008 Brassica napus var napus Nutrition 0.000 claims description 6
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims description 6
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 6
- 244000188595 Brassica sinapistrum Species 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 241000283898 Ovis Species 0.000 claims description 6
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 6
- 235000004443 Ricinus communis Nutrition 0.000 claims description 6
- 240000000528 Ricinus communis Species 0.000 claims description 6
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000010696 ester oil Substances 0.000 claims description 6
- 235000021323 fish oil Nutrition 0.000 claims description 6
- 239000010460 hemp oil Substances 0.000 claims description 6
- 235000014593 oils and fats Nutrition 0.000 claims description 6
- 239000004006 olive oil Substances 0.000 claims description 6
- 235000008390 olive oil Nutrition 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 claims description 5
- 229920002907 Guar gum Polymers 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000000665 guar gum Substances 0.000 claims description 4
- 229960002154 guar gum Drugs 0.000 claims description 4
- 235000010417 guar gum Nutrition 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229960004544 cortisone Drugs 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 235000021313 oleic acid Nutrition 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 229960004495 beclometasone Drugs 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002842 clobetasol Drugs 0.000 claims description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 2
- 229960002867 griseofulvin Drugs 0.000 claims description 2
- 229960002383 halcinonide Drugs 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 229960002703 undecylenic acid Drugs 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 88
- 210000001519 tissue Anatomy 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 32
- 206010018910 Haemolysis Diseases 0.000 description 23
- 230000008588 hemolysis Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000007788 liquid Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 18
- 210000002615 epidermis Anatomy 0.000 description 16
- 241001116389 Aloe Species 0.000 description 13
- 235000011399 aloe vera Nutrition 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 235000016709 nutrition Nutrition 0.000 description 13
- 230000035764 nutrition Effects 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 201000004624 Dermatitis Diseases 0.000 description 10
- 208000002474 Tinea Diseases 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 206010012504 Dermatophytosis Diseases 0.000 description 7
- 241001460074 Microsporum distortum Species 0.000 description 7
- 230000000474 nursing effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 210000002374 sebum Anatomy 0.000 description 6
- 210000004927 skin cell Anatomy 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 6
- 206010048768 Dermatosis Diseases 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011241 protective layer Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 201000010618 Tinea cruris Diseases 0.000 description 4
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 4
- 208000002894 beriberi Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000013521 mastic Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 3
- VOBDXTSTTMAKHK-VHDCPBDGSA-N 3870-07-3 Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O VOBDXTSTTMAKHK-VHDCPBDGSA-N 0.000 description 3
- 206010058820 Acantholysis Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 229960005040 miconazole nitrate Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 206010005913 Body tinea Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000220324 Pyrus Species 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 244000144987 brood Species 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 210000003701 histiocyte Anatomy 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000021017 pears Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 230000037204 skin physiology Effects 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 210000003859 smegma Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- GWXQTTKUYBEZBP-UHFFFAOYSA-N 1h-benzimidazol-1-ium-2-sulfonate Chemical compound C1=CC=C2NC(S(=O)(=O)O)=NC2=C1 GWXQTTKUYBEZBP-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940124448 dermatologic drug Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 1
- 108700024047 pangamic acid Proteins 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
A plant matrix for the products used to beautify face, nurse skin, protect hair, and treat disease is composed of 100% pure edible plant juice, or 100% pure juice of edible plant and edible oil.
Description
Technical field
The present invention relates to a kind of plant substrates, particularly a kind of 100% or contain the substrate of edible plant living tissue and living tissue liquid.Utilize this substrate can be prepared into various products with various beauty treatments, skin nursing, hair conditioning style and therapeutical effect.
Technical background
Contain a large amount of skin nursing compositions in the root of plant, stem and the leaf, people once utilized some goods nursing skin of making as the composition in the serosity of vegetables such as plants such as Radix et Caulis Opuntiae Dillenii, Aloe or Fructus Cucumidis sativi; For example Chinese patent application discloses a kind of plaque dispelling skin care liquid No. 99112965.2, mainly is made up of Aloe extraction solution, purification glycerol, vitamin e, hydrogenation fish shark alkane, kojic acid and derivant thereof.Its concrete prescription is: get Aloe extraction solution 40%, purification glycerol 5%, Vitamin B15 %, hydrogenation fish shark alkane 10%, kojic acid and derivant 10% thereof.To pack in the container by the composition of above proportioning, stirring gets final product.Chinese patent application discloses the extraction process for purification of a kind of cosmetics and medicinal aloe for No. 92101797.9 for another example.It adopts non-solvent method to extract multiple effective medicinal ingredient in the Aloe, as cosmetics and the medicinal refining raw material of Aloe.This invention is the Aloe juice thermal precipitation of getting scraping, and after the filtration gained Aloe clear liquid is exchanged with ion exchange resin, when pH value reaches 6-7, collects its aloe purificata juice, and low temperature, keeps in Dark Place.
In addition, only be with the certain plants composition in the prior art, for example some composition adding cosmetic kind of Fructus Cucumidis sativi or Aloe etc. is used as effective ingredient.United States Patent (USP) 4,505, disclose a kind of skin treating preparation for No. 902, the effect that particularly has cosmetics, this preparation are substrate by the purified mineral oil of 54.25% weight mainly, for example add other material, 26% weight almond oil, the Aloe juice of 18% weight, the wheat germ oil of 1% weight, 0.5% other material of weight American Avocado Tree wet goods.Those skilled in the art know, and mineral oil is the concise material from oil, are not edible oil.
Also having no talent in the prior art utilizes the whole vital activity of plant living tissue and living tissue liquid to come Direct Nursing skin nutrition and beauty treatment, it is pure more to be out of use, and perhaps becomes the plant living tissue of 100% natural juice or living tissue liquid strengthens effective ingredient as the substrate of skin, mucosa medicine for external use bioavailability and curative effect.
Summary of the invention
The present invention utilizes bionic principle, seeks a kind of material near the human skin cell tissue fluid, reaches the grade that helps skin histology liquid and oozes physiological condition and help the purpose that skin absorbs is utilized this material.Our research is thought, human skin is by epidermis, corium, and the appendages of skin are formed jointly, the normal physiological metabolism of skin and nutrition supply are to realize by the blood circulation in the skin and the secretory function of the appendages of skin, dermal tissue is almost completely realized its Nutrition and Metabolism and excretory by intradermal blood circulation and lymphatic vessel, epidermis then is to lean on the dual function of the blood circulation and the appendages of skin to ensure its metabolism and supply with nutrition, that is to say as long as ensure the function of the blood circulation of skin and the appendages of skin, just can ensure the normal physiological health of dermis of skin and epidermis; The cytohistology index that realizes the skin physiology condition is whether the tissue fluid in the skin histology keeps normal osmotic pressure and the required nutrient substance of cellular metabolism; The balance of skin histology liquid osmotic pressure, determining the metabolism of Skin Cell, no matter how abundant nutrient substance is, if the skin histology osmotic pressure changes, nutrient substance in the tissue fluid just can not be utilized by cell, products of cellular metabolism (as oxygen-derived free radicals) just can not in time be excluded, and skin will tarnish and is old and feeble, and this is the old and feeble easily mechanism of skin; It is revealed as unglazed simple and unadornedly, wrinkling etc. as the skin of a fatigue, and reason is that skin histology liquid osmotic pressure reduces, and is that the tissue fluid between skin histology reduces, and causes corium to dewater relatively; As the skin of an edema, the tissue fluid osmotic pressure increases, and skin histology liquid accumulates a large amount of moisture, thereby causes cell hypoxia; So ensure the normal physiological metabolism of skin, keep the health of skin to set about research from the tissue fluid osmotic pressure of skin, break away from this principle, still be difficult to gather effect, so, medically all cosmetics have been made the conclusion that the damage skin side-effects is all arranged.Another factor that influences skin appearance is the metabolism of epidermis cell, people's epidermis is the tissue of being made up of four big confluent monolayer cells that connects with the epidermis substrate plate, he must the keeper organize osmotic pressure normally, and keeping of his osmotic pressure and nutrition is to lean on the blood vessel side of corium to supply with epidermal basal cell layer, spinous layer, the intercellular tissue fluid metabolism realization of granular layer through substrate plate; The outermost part granular layer of epidermis and all the tissue fluid of corneocytes keep with nutrition then be that the perspiration by sweat gland secretion, the sebum of smegma, the tissue fluid of deep skin histology liquid evaporation are finished jointly; We pass through surface skin member liquid metabolic alterations observational study; confirmed this argumentation fully; thereby the surperficial physiological fluid protection of having established human skin is to lean on the mixed solution that does not have injury with the skin histology liquid phase with the multiple pair cell that becomes to be grouped into nutrition and metabolism function of osmotic pressure; rather than water, more not the chemical substance of injury cell.For this reason, the present invention is conceived to realize the research of its physiological skin care product, utilize bionics principle, with the mixing material of keeping skin histology osmotic pressure of the tissue fluid in plant peel, the stem as the external preparation for skin product, or form with the sebum oil phase according to the requirement of skin metabolism and to comply with the metabolic product of skin tissue cell, thereby invention has been founded and skin common physiology metabolism and promote (more not damage) skin products of cell regeneration.Human skin surface has the emulsive protective layer of one deck, this protective layer is to have the sebum of smegma and the excretory perspiration emulsifying of sweat gland to form, the effect of this emulsion layer on the one hand forms sealing coat to the Nature to skin appearance, keeps the environment of the physiology life of skin; Infiltrate in the epidermis on the one hand, moisten, nutrition epidermal granular layer and cuticular layer cell; The nutrition of this natural formation and protection are the results of human long-term evolution.What adopt in the existing cosmetics is water, perhaps various other materials, and final result is that the grade that does not have to reach normal person's a Skin Cell is oozed osmotic pressure, not only bad for the metabolism of skin, and Skin Cell is produced the low or high damage of oozing.What is interesting is, only be that plant 100% natural juice also can show the human skin cell is had the nutrition nursing role; Its cardinal principle thinks that through our experimentation the grade that the living tissue liquid of plant has a living cells oozes effect, has created the biotic environment condition of cellular metabolism, thereby when improving looks, has fundamentally solved the damage problem of cosmetics to skin.
In order to overcome the deficiencies in the prior art; the object of the present invention is to provide a kind of substrate that only contains edible plant 100% natural juice; this plant juice can contain the living tissue of plant; this substrate can be used separately as cosmetics and drug matrices; also can add edible oil and/or to the oily matter of skin care effect or the medicine of effective dose, use as dermal drug or cosmetic base.The water osmotic pressure of the plant substrates that obtains like this and the osmotic pressure of application on human skin are basic identical, and this substrate does not contain any inorganic salt and other material of extra adding substantially.In other words, this " pure plant juice " no longer adds other any material or water.
Another object of the present invention is to provide the method for preparing edible plants 100% natural juice; And this can be contained living tissue described plant juice, add a certain amount of suspending agent after with activated carbon decolorizing to make cosmetics and medicine for external use substrate such as the beauty treatment of various suspension concentration, skin care item, hair conditioning style.
Another object of the present invention is to also to provide a kind of and comprise edible plant 100% natural juice and edible oil and/or the substrate of the oily matter of skin care effect.This substrate of being made up of water and oil phase can also be mixed and made into a kind of compositions to application on human skin treatment and/or nursing effective substances with other.
A further object of the present invention is to provide a kind of preparation to contain edible plant 100% natural juice and edible oil and oily matter with skin care effect mixes the method for forming substrate; And make various emulsifyings or non-emulsifying externally applied product substrate;
In other words; the present invention adopts edible vegetation water; be preferably 100% natural juice of plant; and the living tissue of plant; or living tissue liquid and edible oil and oily matter with skin care effect come the identical component and the osmotic pressure of apish skin surface protective layer, makes a kind of substrate that has moist, nutrition, nursing skin effect and can improve the biological effectiveness of external used medicine.
But not all plant can be used for preparing substrate of the present invention.As well known to those skilled in the art, certain plants is deleterious to the mankind, or is irritant to human skin, and these plants can not be used.The present invention adopts human edible plant.Human for a long time these plant proofs of using are harmless to the mankind.
Employed term among the present invention " 100% natural juice " or " pure plant juice " are meant pure serosity or the juice of the former plant that obtains after plant is through processing.In the course of processing, can not add any extra water.The natural juice of this kind of plant includes plant living tissue or the living tissue liquid with active function.In the present invention, do not consider possibility because the water that airborne moisture or dampness condense into naturally influences term as herein described " 100% natural juice " or " pure plant juice ".
In one embodiment, the present invention relates to a kind of plant substrates, it comprises edible pure plant 100% natural juice, and this plant juice can contain the living tissue of this plant.This plant juice can contain cell, tissue fluid and the Plant fiber of this plant.
Plant of the present invention comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.Described fruit comprises Fructus Citri tangerinae, Fructus Musae, Fructus Mali pumilae, pears or the like.Preferably include Fructus Lycopersici esculenti, Fructus Cucumidis sativi etc. in the vegetable.Described plant particularly preferably is and comprises Radix et Caulis Opuntiae Dillenii or Aloe.These plant liquids contain the plant colloid a bit.
In another embodiment of the invention, described substrate preferably also comprises edible oil or oleic acid.Described oils and fats comprises animal oil, Vegetable oil lipoprotein, synthetic ester oil or their compound lard.Vegetable oil lipoprotein comprises soybean oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, hemp-seed oil, castor bean oil, rapeseed oil, Oleum sesami, Semen Lini oil, canola, Soviet Union's oil, Semen Maydis oil, olive oil.Animal oil comprises Adeps Sus domestica, Adeps Caprae seu ovis, Adeps Bovis seu Bubali, chicken oil, duck oil, fish oil.Edible oil also comprises fatty acid or or oleic acid, linoleic acid, stearic acid, monoglyceride, semi-saturation fatty acid.
The oils and fats that uses among the present invention can not comprise what those cannot eat, paraffin oil for example, natural or synthetic oils and fats of mineral wet goods etc.
In substrate of the present invention, can add an amount of suspending agent, directly form the external preparation for skin product of spendable various suspension concentration.
In substrate of the present invention, described pure plant living tissue and natural juice and edible oil or have the weight ratio 1 of the oiliness composition of skin care effect: 99-99: 1, preferably 10: 90-90: 10, more preferably 30: 70-70: 30.For example plant juice and edible oil weight ratio can be 10: 90; 20: 80; 30: 70; 40: 60; 50: 50; 60: 40; 70: 30; 80: 20; 90: 10.
The invention still further relates to the preparation method of substrate of the present invention, may further comprise the steps: (A) edible plants is pulverized, wear into vegetable slurries; (B) filter described serosity, supernatant that must this serosity, after 80-140 degree centigrade of sterilization, a plant colloid.
In addition, in the method for the present invention, can further include,, generate a transparent or translucent colloid through further milled processed to the processing of decolouring of described plant supernatant.
In the method for the invention, described plant juice can contain cell, tissue fluid and the Plant fiber of this plant.Described plant comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.
The invention still further relates to a kind of preparation method of substrate, comprise, add emulsifying pot internal emulsification, homogenizing with emulsifying agent with after edible oil or oleic acid and the plant juice sterilization.In the method, described plant juice can contain cell, tissue fluid and the Plant fiber of this plant.Described plant comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.Described edible oil comprises animal oil, Vegetable oil lipoprotein, synthetic ester oil or their compound lard.Described Vegetable oil lipoprotein comprises soybean oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, hemp-seed oil, castor bean oil, rapeseed oil, Oleum sesami, Semen Lini oil, canola, Soviet Union's oil, Semen Maydis oil, olive oil.Described animal oil comprises Adeps Sus domestica, Adeps Caprae seu ovis, Adeps Bovis seu Bubali, chicken oil, duck oil, fish oil.Described edible oil comprises fatty acid or or oleic acid, stearic acid, monoglyceride, semi-saturation fatty acid.
Described emulsifying agent comprises the ester of xylitol (XSE), sorbitan monostearate (SMS), six polyglyceryl fatty acid esters (PGFE), monoglyceride, silicone emulsifiers or the like.
Through the substrate that method of the present invention obtains, it is characterized in that the fructose content of this substrate is less than 5% through after the decolouring processing.
In addition, the invention still further relates to a kind of medicinal substrate, it comprises edible plant 100% natural juice or contains the substrate that living tissue 100% plant juice directly forms.This substrate can also add edible oil and/or oleic acid, also can add skin treating effective dose of medicine thing.Described medicine comprises the hormones that skin is had pharmacological action, for example cortisone, hydrocortisone, prednisolone, methylprednisolone, prednisolone, beclometasone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, halcinonide (halcinonidedcorten) and clobetasol etc.Antibacterial, for example: sulfonamides, quinolione class, antibiotic such as polygynax etc.; Antifungal, for example ketoconazole, miconazole, griseofulvin, bifonazole, clotrimazole, undecylenic acid etc.Preferred medicine comprises: gently change cortisone, fluocinolone acetonide, miconazole nitrate, the bent An Naide of acetic acid, polygynax.
The weight ratio about 1 of described pure plant juice and edible oil: 99-99-1.Preferably 10: 90-90: 10, more preferably 30: 70-70: 30.
The invention still further relates to a kind of cosmetic base, comprise edible pure plant 100% natural juice.In this substrate, can also further add edible oil.The weight ratio about 1 of described pure plant juice and edible oil: 99-99-1.In this cosmetic base, described plant comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.Described fruit comprises Fructus Citri tangerinae, Fructus Musae, Fructus Mali pumilae, pears or the like.Preferably include Fructus Lycopersici esculenti, Fructus Cucumidis sativi etc. in the vegetable.Described plant particularly preferably is and comprises Radix et Caulis Opuntiae Dillenii or Aloe.These plant liquids contain the plant colloid a bit.
In another embodiment of cosmetic base of the present invention, described substrate preferably also comprises edible oil and/or oleic acid.Described oils and fats comprises animal oil, Vegetable oil lipoprotein, synthetic ester oil or their compound lard.Vegetable oil lipoprotein comprises soybean oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, hemp-seed oil, castor bean oil, rapeseed oil, Oleum sesami, Semen Lini oil, canola, Soviet Union's oil, Semen Maydis oil, olive oil.Animal oil comprises Adeps Sus domestica, Adeps Caprae seu ovis, Adeps Bovis seu Bubali, chicken oil, duck oil, fish oil.Edible oil also comprises fatty acid, oleic acid, linoleic acid, stearic acid, monoglyceride, semi-saturation fatty acid.
In cosmetic base of the present invention, can also add skin treating effective dose of medicine thing or skin protection material.Described skin protection material is well known to a person skilled in the art, preferably includes sunscreen, skin anti-aging agent, skin-nourishing agent, anti-wrinkle agent.
Can add the Plant fiber of this plant or the Plant fiber of other plant, perhaps this plant and other plant or Plant fiber's composite fibre in addition in various substrate of the present invention.The fiber that adds can more effectively form the protective layer of skin that is made of substrate of the present invention.
Substrate of the present invention can directly be used as hair care setting product, also can be directly as gel, and the product of mousse or gel sample uses.In addition, can comprise binding agent in this substrate, described binding agent is carbopol or guar gum and their mixture.
This substrate of the present invention is compared with dosage forms such as ointment with traditional cosmetics or skin: the perspiration of this substrate and application on human skin and cortex secretions constitute protective layer and merge easily, do not influence the drainage of skin metabolism product.Because substrate of the present invention contains plant living tissue liquid and plant living tissue, it is directly to the repair of epiderm skin corneocyte; Help the regeneration of epidermis cell.Be used for the external preparation for skin medicine and make substrate, not only improve the bioavailability of effective ingredient, and, because of having the effect that recovers the skin physiology function, significantly improve the curative effect of medicine.Created the microecological environment of host's skin histology, made histiocyte recover normal immunity.
Description of drawings
Fig. 1 is illustrated in skin surface use substrate of the present invention after, human sweat's microdroplet is discharged, re-absorbed performance.
Fig. 2 is illustrated in the erythrocyte hemolysis experiment, when having only substrate of the present invention, normal saline and D distilled water in the test tube, the letter " A " that can find the test tube back side can be through the liquid in the test tube, but because substrate of the present invention is faint yellow, so it is fuzzy that letter " A " shows slightly, and other two pipes can be high-visible.
Fig. 3 is illustrated in the erythrocyte hemolysis experiment, adds 30 μ l packed cell volumes, the observed result after shaking up at once in test tube.
Fig. 4 is illustrated in the erythrocyte hemolysis experiment, continues 7 minutes (Fig. 4 A) at interval respectively, 24 minutes (Fig. 4 B) and 1 hour (Fig. 4 C) and 1 hour 56 minutes (Fig. 4 D), the haemolysis result of 2 hours 11 minutes (Fig. 4 E) and 12 hours 09 minutes (Fig. 4 F).
Fig. 5 is illustrated in the erythrocyte hemolysis experiment, respectively in 12 hours 11 minutes (Fig. 5 A) in interval, 15 hours 11 minutes (Fig. 5 B), the haemolysis result after 16 hours 14 minutes (Fig. 5 C) and 18 hours 14 minutes (Fig. 5 D).Haemolysis does not appear in substrate pipe of the present invention and saline tube always.
Below with reference to embodiment and accompanying drawing, describe embodiment of the present invention in detail, following embodiment only is to explanation of the present invention, and non-limiting meaning.
Specific embodiments
The preparation of embodiment 1 Caulis et Folium Lactucae sativae juice
100 kilograms in fresh food Caulis et Folium Lactucae sativae is plucked in choosing; Clean three times, use the filament cutter shredding.Caulis et Folium Lactucae sativae after shredding is processed with colloid mill at once, the distance of the tooth pitch of colloid mill being transferred to 1mm, 20 μ m and 0.2 μ m is ground respectively earlier, get Caulis et Folium Lactucae sativae and organize suspension, centrifugal with centrifuge, the filter cloth net is at 150 orders～250 orders, drive away the solids Plant fiber, collect filtrate in transparent vessel.Filtrate is placed the natural subsidence layering, get Caulis et Folium Lactucae sativae and organize about 33 kilograms of supernatant.
The preparation of embodiment 2 Sucus Mali pumilae
Fresh apple is plucked in choosing; Clean three times, pulverize with pulverizer.Fructus Mali pumilae is after crushed processed with colloid mill at once, the distance of the tooth pitch of colloid mill being transferred to 1mm, 20 μ m and 0.2 μ m is ground respectively earlier, get the apple tissue suspension, centrifugal with centrifuge, the filter cloth net is at 150 orders～250 orders, drive away the solids Plant fiber, collect filtrate in transparent vessel.Filtrate is placed the natural subsidence layering, get about 60 kilograms of apple tissue and supernatant.
Embodiment 3 Radix et Caulis Opuntiae Dillenii juices' preparation
1000 kilograms of fresh food Radix et Caulis Opuntiae Dilleniis are plucked in choosing; Drive away scar tissue and thorn; Clean three times, use the filament cutter shredding.Radix et Caulis Opuntiae Dillenii after shredding is processed with colloid mill at once, the distance of the tooth pitch of colloid mill being transferred to 1mm, 20 μ m and 0.2 μ m is ground respectively earlier, get Radix et Caulis Opuntiae Dillenii and organize suspension, centrifugal with centrifuge, the filter cloth net is at 150 orders～250 orders, drive away the solids Plant fiber, collect filtrate in transparent vessel.Filtrate is placed the natural subsidence layering, get about 480 kilograms of Radix et Caulis Opuntiae Dillenii tissue and supernatant.
Can in described filtrate, add copper sulfate, be used to protect the color of Radix et Caulis Opuntiae Dillenii.
The preparation of embodiment 4 Radix et Caulis Opuntiae Dilleniis and edible oil substrate
20 kilograms Oleum sesami, 8 kilograms of stearic acid, 3 kilograms of glyceryl monostearates are put into the oil phase jar, and 80rpm stirs, and is heated to 88 ℃ ± 2 ℃ simultaneously, insulation sterilization 40m minute, the mixture of winning.
Organize supernatant, 2 kilograms of triethanolamine to put into the water jar 66.4 kilograms of Radix et Caulis Opuntiae Dilleniis that obtain through embodiment 3,80rpm stirs, and is heated to 95 ℃ simultaneously, and insulation sterilization 60 minutes gets second mixture.
The guar gum of first and second mixture that obtain and 0.6 kilogram is continued to mix at vacuum emulsification machine (400 types, state-run Changshu Chinese traditional medicine machine instrument factory), and mixing speed is 120rpm; After treating fully to mix, be under 90 ℃, mixing speed is controlled to be 80rpm, start homogenizer 4 minutes in temperature.
When treating that temperature drops to 30 ℃ ± 2 ℃, rotating speed is controlled at 10rpm, squeeze into filtrated air after, a mastic, promptly invent described substrate.
The pharmaceutical composition that embodiment 5 is made by substrate of the present invention
In the substrate that embodiment 4 obtains, add following ingredient and can prepare the ointment that contains triamcinolone acetonide acetate 1g miconazole nitrate 10g polygynax 3,000,000 u in per 10 substrate.
Specifically, polygynax is put in the water pot, the deep fat phase that takes a morsel, it is standby that adding miconazole nitrate, triamcinolone acetonide acetate and Butylated hydroxyanisole (BHA) stir into the suspension insulation.
Successively water, oil phase vacuum are sucked mulser (400 types, state-run Changshu Chinese traditional medicine machine instrument factory), add the triamcinolone acetonide acetate suspension under 80 ℃ of high-speed stirred.High-speed stirred, to 75 ± 2 ℃ of homogenizing 5-10min, to about 60 ℃, middling speed stirs, and extremely about 35-40 ℃ goes out cream.The intermediate products ointment is packed through fill after the assay was approved.
Though the ointment that present embodiment obtains can all have certain curative effect to dermopathic medicine for external use such as beriberi, eczema, tinea cruris, dermatitis, tinea corporis.And after the treatment, by skin regeneration repair mechanism prevention of recurrence.Embodiment 6: the preparation of sun-proof gel
The Radix et Caulis Opuntiae Dillenii tissue fluid that embodiment 3 is obtained is heated to 75 ℃ for 50 kilograms, adds 1.5% active carbon (granularity of activated carbon is 200 orders～300 orders), stirring, constant temperature 40 minutes; To contain the filter cloth surface that the melt and dissolved thing of 80% kieselguhr (300 order) evenly is applied to plate filter simultaneously, coating thickness is 2 millimeters; Be added with the tissue fluid of active carbon with the plate filter filtration under diminished pressure of handling well through kieselguhr, the filtrate that obtains is the Radix et Caulis Opuntiae Dillenii tissue fluid of decolouring.
According to well known to a person skilled in the art method, with the tissue fluid of the raw material of accurate weighing decolouring Radix et Caulis Opuntiae Dillenii, binding agent is that carbopol (Carbopol2020) or guar gum or their mixture, propylene glycol, glycerol and methyl hydroxybenzoate and germall A put into vacuum tank, airtight disappear the heating 75 ℃ 90 minutes, the while continuous stirring, mixing speed is controlled at 100rpm.
Through behind the homogenizing, add for example basic benzimidazole sulfonic acid of water solublity sunscreen, its addition is well known to a person skilled in the art, stirred 20 minutes through 150rpm, homogenizing 5 minutes, constant temperature 20 minutes, evacuation makes vacuum reach 0.09MP simultaneously.
In addition, can add essence as required, and mix.When temperature dropped to 30 ℃ ± 2 ℃, rotating speed was controlled at 10rpm, squeezes into filtrated air, mastic is pressed in the sterile chamber seals up for safekeeping, and mastic completes.
The sampling of mastic through completing is detected, carry out an analysis such as stability, pH, microorganism; After every index was qualified, installation required fill in glass container; Behind packaging process, be sun-proof gel finished product.
The experiment of experimental example 1 erythrocyte hemolysis
Normal haemolysis is directly related with the osmotic pressure of erythrocyte surrounding, and simultaneously also relevant with the nutrition of surrounding, the former causes direct haemolysis, and the latter causes indirect hemolysis.Substrate of the present invention and normal saline and distilled water haemolysis situation under the same conditions that this laboratory observation obtains through the foregoing description 3 are to detect the influence of this substrate to erythrocyte hemolysis.Materials and methods 1. is through new zealand white rabbit ear central artery blood drawing 5ml, adds to be placed with the cover in the conical flask of heparin (the medical scientific and technological industry of Second Military Medical University, PLA's political affairs Xiang service department chemical reagent research department), and anticoagulation is made in rapid jolting.2. simultaneously the substrate of the present invention of stored frozen is placed a beaker heat fused, about altogether 50ml, centrifugal 2000rpm under the room temperature, 20 minutes, get supernatant, place a 50ml centrifuge tube, 70 ℃ of water-baths 1 hour.3. get above-mentioned anticoagulation 2ml, place a 5ml teat glass, add the 6ml normal saline, abundant mixing, centrifugal 1500rpm under the room temperature 5 minutes, abandons clean supernatant, repeat this step twice, supernatant is clear, shows that erythrocyte is cleaned, abandons clean supernatant, obtain the rabbit erythrocyte hematocrit, 4 ℃ of refrigerators are preserved.4. get three test tubes, be fixed together side by side, all be marked with English alphabet " A " with the same level of marking pen on the opposite of three test tube sightingpistons with adhesive plaster.5. add 5ml substrate of the present invention, 5ml normal saline and 5ml distilled water from left to right according to this, digital camera is taken a picture.Observe the situation that sees through of test tube back side letter " A ".6. add 30 μ l rabbit erythrocyte hematocrits subsequently, shake up at once, write down the situation that sees through of test tube back side letter " A " once more with digital camera.
7. later certain hour is at interval observed the haemolysis situation in three test tubes, then shakes up as erythroprecipitin.At any time record.Experimental result is when having only substrate of the present invention, normal saline and distilled water in the test tube, the letter " A " that can find the test tube back side can be through the liquid in the test tube, but, blur so letter " A " shows slightly, and other two pipes can clearly see through (Fig. 2) because substrate of the present invention is faint yellow.Add 30 μ l packed cell volumes, shake up at once, when observing test tube back side letter " A ", find clear the seeing through of letter " A " in the distillation water pipe, illustrate that erythrocyte dissolves immediately, other two pipes can not see through, illustrate that erythrocyte fails dissolving, structure be kept perfectly (Fig. 3).Later certain hour at interval, observe preceding two pipes and do not occur haemolysis always, though the two is haemolysis (Fig. 4 to Fig. 5) not all, but situation is different, substrate test tube of the present invention is evenly muddy, show cell precipitation not, and saline tube erythroprecipitin phenomenon is fairly obvious, so that, need mixing again in order to observe haemolysis.
With reference to Fig. 2, wherein be substrate pipe of the present invention, saline tube and distillation water pipe from left to right according to this.When having only substrate of the present invention, normal saline and distilled water in the test tube, the letter at the test tube back side " A " can see through the liquid in the test tube, and substrate of the present invention is faint yellow, blurs so letter " A " shows slightly.
Referring to Fig. 3, in each test tube, add 30 μ l packed cell volumes, shake up at once, clear the seeing through of letter " A " in the distillation water pipe illustrates that erythrocyte dissolves immediately.Other two pipes can not see through, and illustrate that erythrocyte does not dissolve.Fig. 4 shows 7 minutes (Fig. 4 A) at interval, 24 minutes (Fig. 4 B) and 1 hour (Fig. 4 C) and 1 hour 56 minutes (Fig. 4 D), the haemolysis result after 2 hours 11 minutes (Fig. 4 E) and 12 hours 09 minutes (Fig. 4 F).
Referring to Fig. 5,12 hours 11 minutes (Fig. 5 A) at interval, 15 hours 11 minutes (Fig. 5 B), though 16 hours 14 minutes (Fig. 5 C) and observed substrate pipe of the present invention after (Fig. 5 D) in 18 hours 14 minutes and haemolysis does not appear in saline tube always is the two equal haemolysis not.
Normocytic cell membrane fragility is bigger, and osmotic pressure is changed sensitivity, and the reduction of osmotic pressure or rising can make erythrocyte fragmentation or shrinkage.In addition, when anoxia, hypoxia or malnutrition, cell membrane can be impaired indirectly because energy is under-supply, causes membranolysis, causes haemolysis.This moment the Na on the cell membrane
+-K
+Important enzymatic activity such as ATP enzyme, adenosine triphosphatase (ATPase) reduces, and causes the Active transport dysfunction, makes the inside and outside ion redistribution of cell (ionic equilibrium is not normal), mainly is Na
+At intracellular retention and K
+By discharging in the cell, but Na
+Retention than K
+Discharge be many, the result causes the rising of osmotic pressure in the cell, moisture is to enter passively in the cell, causes cellular edema, causes cell rupture at last.Haemolysis at once takes place in the distillation water pipe in this experiment, exactly because the osmotic pressure around the erythrocyte is starkly lower than the osmotic pressure in the cytoplasm, large quantity of moisture enters cell by this semipermeable membrane of cell membrane in the extremely short time, cause cellular edema, cause erythrocyte fragmentation to become very little fragment, barrier effect to light significantly weakens, the reflected light permeability is increased, therefore can very clearly see the letter " A " at the test tube back side, and substrate pipe of the present invention and saline tube, because haemolysis does not take place, erythrocyte is complete, barrier effect to light is very strong, and the reflected light at the back side can not see through liquid, therefore can't see letter " A ".
The biological effect research report of experimental example 2 substrate of the present invention
Though all have certain curative effect at dermopathic medicine for external use such as beriberi, eczema, tinea cruris, dermatitis, tinea corporis in the prior art at present, but this type of dermopathic outbreak once more is the common difficulty of all external preparation for skin medicines after treatment, and studies the Therapeutic Method of its prevention of recurrence.In this experimental example, by utilizing application on human skin fungal infection model, observe cause the tinea fungus in the skin regeneration repair process to the histiocytic influence of epidermis.The substrate of the present invention of utilizing embodiment 5 to obtain, study the biological effect of substrate of the present invention as external preparation for skin medicine substrate, be testing drug with PIKANG SHUANG and PIYANPING medicine again, these two kinds of medicines are made substrate with substrate of the present invention, carry out the contrast of clinical treatment effect with medicine of the same race with chemical matrix.The direct substrate of using the embodiment of the invention 5 to obtain on people's skin plays moist protective effect to people's skin, and people's skin perspiration normal (referring to Fig. 1).
The biological effect experiment of substrate of the present invention can show as: (A) can make epiderm skin cuticular layer and other each layer attenuates, help the dermal osmosis of active ingredient, improve bioavailability.Before using substrate of the present invention: the keratinization of epidermis layer is thicker, and other each layer of epidermis is also thicker.Use the back: the obvious attenuation of keratinization of epidermis layer, other each layer of epidermis be obviously attenuation also.(B) can make the growth of epidermis substrate and acantholysis cell vigorous, strengthen the disease-resistant and immunocompetence of local skin tissue.Before the use: substrate and acantholysis cell growth are inactive.Use the back: substrate and acantholysis cell active growth.(C) impel the sebaceous gland sebum to drain, the skin surface lipid acid metabolic is strengthened, improve antiinflammatory, the anti-infection ability of skin self.Before the use: the sebaceous gland cell is full, and sebum discharges slowly, is cubic.Use the back: the sebaceous gland cell becomes flat, and sebum discharges to be accelerated.(D) impel the variation of dermatophytosis and pathogenic bacterium, the prevention dysbacteriosis reduces and the prevention cytotoxicity, ensures the life physiological status of skin, and the prevention dermatosis is an example with Propiobacterium and Candida albicans:
Propionibacterium acnes: before the use: propionibacterium acnes is shaft-like.Use the back: propionibacterium acnes becomes the club shape.
Candida albicans: before the use: brood cell's generation rate is 90%.Use the back: brood cell's generation rate is 0.5%.PIKANG SHUANG is utilized the clinical control of the embodiment of the invention 3 substrate (only being Radix et Caulis Opuntiae Dillenii fumet) and chemical matrix
| Biological effect | Relapse rate % | |
| Substrate chemical matrix P value of the present invention | Quan Xiangwu | Beriberi eczema tinea cruris dermatitis |
| ??2.5???????5.4??????0.5??????4.6 | ||
| ??95.1??????92.4?????96.2?????93.6 | ||
| ??＜0.001???＜0.001??＜0.001??＜0.001 |
Result: use the PIKANG SHUANG of substrate of the present invention and the PIKANG SHUANG clinical efficacy contrast of chemical matrix that significant difference is arranged.
PIYANPING is utilized the clinical control of substrate of the present invention and chemical matrix
| Biological effect | Relapse rate % | |
| Substrate chemical matrix of the present invention | Quan Xiangwu | Dermatophytosis dermatitis eczema |
| ????3.5?????6.9?????7.1 | ||
| ????97.2????96.2????91.4 |
| The P value | ??＜0.001?＜0.001?＜0.001 |
Result: use the PIKANG SHUANG of substrate of the present invention and the PIKANG SHUANG clinical efficacy contrast of chemical matrix that significant difference is arranged.
Prior art thinks that the pathogenic factor of common skin diseases such as beriberi, eczema, tinea cruris, dermatitis has three: one, host tissue fail in time to recover physiological status after dermopathic morbidity is controlled; Its two, pathogenic bacterium can not be fundamentally controlled, only be temporarily to be in inhibitory state, its three, surrounding can not improve.After dermatosis is controlled, more than the existence of any one reason all can make and have a relapse.Substrate of the present invention is applied to dermatologic medicine, can effectively prevent the dermatosis recurrence.This is because substrate of the present invention contains the required multiple nutrients composition of skin histology metabolism, owing to have the isoosmotic pressure close with skin, and has Repiration at skin surface, after dermatosis is controlled, host tissue can in time obtain prescribing adequate nutrition, impaired skin is repaired quickly, recovers its physiological status; In addition, the biological effect of substrate of the present invention has played the basic effect of prevention dermatosis recurrence; Moreover created the microecological environment of host's skin histology, and make histiocyte recover normal immunity, avoid the generation of pathogenic bacteria Resistant strain, improved the bioavailability of active ingredient simultaneously.
Experimental example 3 substrate of the present invention dynamic observe treatment tinea pedis drug effect
In this experimental example, observe of the effect of the pharmaceutical composition of above-mentioned experimental example 5 described substrate preparations to dermatophytosis.Experimental technique is to 10 routine vesicle types and squama type tinea pedis patient local topical said composition treatment respectively.Difference bark fetching (squama) crumb 10%KOH solwution method microscopy dermatophytosis before and after treatment.Simultaneously squama type tinea pedis patient's squama is wherein done tissue slice HE dyeing, the variation of microscopy dermatophytosis mycelia, spore and cell tissue etc.The result is tinea pedis patient's clinicing symptom observation 100% recovery from illness for the treatment of for 4 weeks through said composition, but skin (squama) bits microscopy dermatophytosis has 9 examples to be positive, and only 1 example is negative.Treated for 4 weeks again, still have 1 example positive.This example patient finds mycelia once more in squama summer next year, after the treatment of 6 weeks, dermatophytosis is negative again.The painted tissue of microscopy HE has notable difference before and after the treatment.
This shows by the pharmaceutical composition of substrate of the present invention preparation antipruritic, antibacterial effect is remarkable, can see and quicken the compensatory orthogenesis of skin lesion position epidermis cell.
The present invention is limited in it in scope of specific embodiment described herein.Really, apparent to one skilled in the art to multiple modification of the present invention from the foregoing description except those are described in this article, and fall in the protection domain of claims.
Claims (55)
1. external preparation for skin plant substrates, the water that it is characterized in that it is edible pure plant 100% natural juice.
2. substrate as claimed in claim 1 is characterized in that the osmotic pressure of the water osmotic pressure of this plant substrates and application on human skin is basic identical, and this substrate does not contain substantially and adds inorganic salt.
3. substrate as claimed in claim 1 is characterized in that described plant juice can contain the cell of this plant, tissue, tissue fluid and Plant fiber.
4. substrate as claimed in claim 1 is characterized in that described plant comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.
5. substrate as claimed in claim 1 is characterized in that comprising edible oil and/or edible oleic acid.
6. substrate as claimed in claim 5 is characterized in that described oils and fats comprises animal oil, Vegetable oil lipoprotein, synthetic ester oil or their compound lard.
7. substrate as claimed in claim 6 is characterized in that described Vegetable oil lipoprotein comprises soybean oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, Testa oryzae oil, hemp-seed oil, castor bean oil, rapeseed oil, Oleum sesami, Semen Lini oil, canola, Soviet Union's oil, Semen Maydis oil, olive oil.
8. substrate as claimed in claim 6 is characterized in that described animal oil comprises Adeps Sus domestica, Adeps Caprae seu ovis, Adeps Bovis seu Bubali, chicken oil, duck oil, fish oil.
9. as claim 1 or 5 described substrate, it is characterized in that described edible oil comprises fatty acid or or oleic acid, stearic acid, monoglyceride, semi-saturation fatty acid.
10. substrate as claimed in claim 5 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 1: 99-99: 1.
11. substrate as claimed in claim 10 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 10: 90-90: 10.
12. substrate as claimed in claim 10 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 30: 70-70: 30.
13. substrate as claimed in claim 5 is characterized in that adding the Plant fiber of this plant or the Plant fiber of other plant, perhaps this plant and other plant or Plant fiber's composite fibre in addition.
14. the preparation method of a substrate as claimed in claim 1 may further comprise the steps: a) edible plants is pulverized, wear into vegetable slurries; B) filter described serosity, supernatant that must this serosity, after 80-140 degree centigrade of sterilization, a plant colloid.
15. method as claimed in claim 14 is characterized in that being added with the plate filter filtration under diminished pressure of handling well through kieselguhr the vegetable slurries of active carbon, the supernatant of the decolouring that obtains.
16. the described method of claim 14 is characterized in that described plant juice can contain the cell of this plant, tissue fluid and Plant fiber.
17. method as claimed in claim 14 is characterized in that described plant comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.
18. method as claimed in claim 14 is characterized in that adding the Plant fiber of this plant or the Plant fiber of other plant, perhaps this plant and other plant or Plant fiber's composite fibre in addition.
19. the preparation method of a substrate as claimed in claim 14 is characterized in that the step that comprises is: with edible oil and/or oleic acid or and the sterilization of pure plant juice after, add emulsifying pot internal emulsification, homogenizing with emulsifying agent.
20. method as claimed in claim 19 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 1: 99-99: 1.
21. method as claimed in claim 19 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 10: 90-90: 10.
22. method as claimed in claim 19 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 30: 70-70: 30.
23. method as claimed in claim 19 is characterized in that described edible oil comprises animal oil, Vegetable oil lipoprotein, synthetic ester oil or their compound lard.
24. method as claimed in claim 23 is characterized in that described Vegetable oil lipoprotein comprises soybean oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, hemp-seed oil, castor bean oil, rapeseed oil, Oleum sesami, Semen Lini oil, canola, Soviet Union's oil, Semen Maydis oil, olive oil.
25. method as claimed in claim 23 is characterized in that described animal oil comprises Adeps Sus domestica, Adeps Caprae seu ovis, Adeps Bovis seu Bubali, chicken oil, duck oil, fish oil.
26. method as claimed in claim 23 is characterized in that described edible oil comprises fatty acid, oleic acid, linoleic acid, stearic acid, semi-saturation fatty acid.
27. method as claimed in claim 19 is characterized in that adding the Plant fiber of this plant or the Plant fiber of other plant, perhaps this plant and other plant or Plant fiber's composite fibre in addition.
28. a substrate that obtains through the described method of claim 14 is characterized in that the fructose content of the substrate that the process decolouring is handled is less than 5%.
29. a medicinal substrate, its water are edible pure plant 100% natural juice.
30. substrate as claimed in claim 29 is characterized in that also comprising edible oil and/or oleic acid.
31., it is characterized in that further comprising skin treating effective dose of medicine thing as claim 29 or 30 described substrate.
32. substrate as claimed in claim 31 is characterized in that described medicine comprises the effective hormones of skin treating, antibacterial, antifungal.
33. substrate as claimed in claim 32, it is characterized in that described medicine comprises: cortisone, hydrocortisone, prednisolone, methylprednisolone, prednisolone, beclometasone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, halcinonide, clobetasol, sulfonamides, quinolione class, polygynax, ketoconazole, miconazole, griseofulvin, bifonazole, clotrimazole, undecylenic acid.
34. substrate as claimed in claim 29 is characterized in that adding the Plant fiber of this plant or the Plant fiber of other plant, perhaps this plant and other plant or Plant fiber's composite fibre in addition.
35. substrate as claimed in claim 30 is characterized in that the weight ratio 1 of wherein said pure plant juice and edible oil: 99-99: 1.
36. substrate as claimed in claim 35 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 10: 90-90: 10.
37. substrate as claimed in claim 36 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 30: 70-70: 30.
38. a cosmetic base, its water are edible pure plant 100% natural juice.
39. substrate as claimed in claim 38 is characterized in that the osmotic pressure of the water osmotic pressure of this plant substrates and application on human skin is basic identical, and this substrate does not contain substantially and adds inorganic salt.
40. substrate as claimed in claim 38 is characterized in that also comprising edible oil.
41., it is characterized in that further comprising to skin treating effective dose of medicine thing as claim 38 or 40 described substrate.
42. substrate as claimed in claim 39 is characterized in that wherein said pure plant juice and edible oil and/or oleic weight ratio 1: 99-99: 1.
43. substrate as claimed in claim 41 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 10: 90-90: 10.
44. substrate as claimed in claim 42 is characterized in that described pure plant juice and edible oil and/or oleic weight ratio are 30: 70-70: 30.
45. substrate as claimed in claim 41 is characterized in that described medicine comprises sunscreen, skin anti-aging agent, skin-nourishing agent, anti-wrinkle agent.
46. substrate as claimed in claim 38 is characterized in that also comprising binding agent.
47. substrate as claimed in claim 38 is characterized in that described plant juice can contain the cell of this plant, tissue, tissue fluid and Plant fiber.
48. want 38 described substrate as right, it is characterized in that described plant comprises edible fruit, vegetable and Cactaceae or Aloeaceae plant.
49. substrate as claimed in claim 38 is characterized in that comprising edible oil and/or edible oleic acid.
50. substrate as claimed in claim 49 is characterized in that described oils and fats comprises animal oil, Vegetable oil lipoprotein, synthetic ester oil or their compound lard.
51. substrate as claimed in claim 50 is characterized in that described Vegetable oil lipoprotein comprises soybean oil, Oleum Arachidis hypogaeae semen, Oleum Helianthi, Testa oryzae oil, hemp-seed oil, castor bean oil, rapeseed oil, Oleum sesami, Semen Lini oil, canola, Soviet Union's oil, Semen Maydis oil, olive oil.
52. substrate as claimed in claim 50 is characterized in that described animal oil comprises Adeps Sus domestica, Adeps Caprae seu ovis, Adeps Bovis seu Bubali, chicken oil, duck oil, fish oil.
53. substrate as claimed in claim 49 is characterized in that described edible oil comprises fatty acid or or oleic acid, stearic acid, monoglyceride, semi-saturation fatty acid.
54. substrate as claimed in claim 46 is characterized in that described binding agent is carbopol or guar gum and their mixture.
55., it is characterized in that to add the Plant fiber of this plant or the Plant fiber of other plant, perhaps this plant and other plant or Plant fiber's composite fibre in addition as claim 46 or described substrate.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021201382A CN100506283C (en) | 2002-05-21 | 2002-05-21 | Plant substrates |
| CNA2008101496526A CN101433719A (en) | 2002-05-21 | 2002-05-21 | External-use substrate for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021201382A CN100506283C (en) | 2002-05-21 | 2002-05-21 | Plant substrates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101496526A Division CN101433719A (en) | 2002-05-21 | 2002-05-21 | External-use substrate for skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1459316A true CN1459316A (en) | 2003-12-03 |
| CN100506283C CN100506283C (en) | 2009-07-01 |
Family
ID=29426944
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021201382A Expired - Lifetime CN100506283C (en) | 2002-05-21 | 2002-05-21 | Plant substrates |
| CNA2008101496526A Pending CN101433719A (en) | 2002-05-21 | 2002-05-21 | External-use substrate for skin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101496526A Pending CN101433719A (en) | 2002-05-21 | 2002-05-21 | External-use substrate for skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN100506283C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266373A (en) * | 2011-08-04 | 2011-12-07 | 上海美宝生命科技有限公司 | Skin externally-used matrix for treating scar and preparation method thereof |
| CN104137914A (en) * | 2014-07-14 | 2014-11-12 | 和县绿源油脂有限公司 | Red melon seed oil capable of moistening skin |
| CN105816388A (en) * | 2016-05-13 | 2016-08-03 | 朱正芳 | Skin-caring face-beautifying effervescent tablet and preparation method and application thereof |
| CN106490178A (en) * | 2016-11-21 | 2017-03-15 | 连云港日丰钙镁有限公司 | A kind of coagulator made suitable for bean curd and preparation method thereof |
| CN110678066A (en) * | 2016-05-13 | 2020-01-10 | 洛科威国际有限公司 | Method for producing plant growth substrate |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908406B (en) * | 2012-11-02 | 2013-11-06 | 姜庆贺 | External liniment for treating bedsore |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG71889A1 (en) * | 1997-12-22 | 2000-04-18 | Mitsui Chemicals Inc | ¬Tris(dimethylamino) phosphonioamino¾ tris ¬tris (dimethylamino) phosphoranylideneamino¾ phosphonium dichloride and preparation process thereof |
-
2002
- 2002-05-21 CN CNB021201382A patent/CN100506283C/en not_active Expired - Lifetime
- 2002-05-21 CN CNA2008101496526A patent/CN101433719A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266373A (en) * | 2011-08-04 | 2011-12-07 | 上海美宝生命科技有限公司 | Skin externally-used matrix for treating scar and preparation method thereof |
| CN104137914A (en) * | 2014-07-14 | 2014-11-12 | 和县绿源油脂有限公司 | Red melon seed oil capable of moistening skin |
| CN105816388A (en) * | 2016-05-13 | 2016-08-03 | 朱正芳 | Skin-caring face-beautifying effervescent tablet and preparation method and application thereof |
| CN105816388B (en) * | 2016-05-13 | 2018-06-01 | 朱正芳 | Cosmetology effervescent tablet and its preparation method and application |
| CN110678066A (en) * | 2016-05-13 | 2020-01-10 | 洛科威国际有限公司 | Method for producing plant growth substrate |
| CN106490178A (en) * | 2016-11-21 | 2017-03-15 | 连云港日丰钙镁有限公司 | A kind of coagulator made suitable for bean curd and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101433719A (en) | 2009-05-20 |
| CN100506283C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230112199A1 (en) | Marine extract compositions and methods of use | |
| Eshun et al. | Aloe vera: a valuable ingredient for the food, pharmaceutical and cosmetic industries—a review | |
| KR101183075B1 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
| CN101766656A (en) | Combination containing mushroom polysaccharide and preparation method thereof | |
| KR102096414B1 (en) | Cosmetic composition for improving of acne skin | |
| US7897154B2 (en) | Dermal drops | |
| Chelu et al. | Aloe vera-based hydrogels for wound healing: Properties and therapeutic effects | |
| CN100506283C (en) | Plant substrates | |
| Kumari et al. | Wound healing Activities of the bioactive compounds from Micrococcus sp. OUS9 isolated from marine water | |
| CN106511218A (en) | Emulsion capable of removing acne | |
| CN100488381C (en) | Propolis ganoderma lucidum spore, dried black fungus polysaccharide compounded soft capsule and preparing process therefor | |
| CN110051626B (en) | Two-phase oil preparation and application thereof | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| CN109602681A (en) | Application of the leech body surface secretion in preparation anti-inflammatory anti-acne skin care item | |
| Meilawaty et al. | The effect of cassava (Manihot esculenta) leaf extract on COX-2 expression in the neutrophil cell culture exposed to the lipopolysaccharide of Escherichia coli (in-vitro study) | |
| KR100602924B1 (en) | Skin perparation for external use containing purpuricenus temminckii frass as the active ingredient | |
| CN107897808A (en) | A kind of tree peony ferment jelly preparation method | |
| WO2006029605A1 (en) | Method and active ingredient for combating plasmodia | |
| Suárez et al. | Propolis: Patents and technology trends for health applications | |
| CN1383887A (en) | Antisenility medicine composition and its prepn | |
| US20220110977A1 (en) | Compositions and methods for treating and preventing viral infections | |
| RU2475245C1 (en) | Ointment for skin pecilomycosis | |
| CN108159247B (en) | Protective composition containing peach blossom extract and application thereof | |
| Fu et al. | Study on antioxidation effect of polyphenols from pomegranate peel in vivo | |
| CN1279005A (en) | Artificial culture method and application of Jiaotuoluo or its mycelium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANTOU MEBO PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: XU RONGXIANG Effective date: 20110510 Owner name: XU RONGXIANG |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100075 ROOM 401, 21/F, FANGGUYUAN YIQU, FANGZHUANG RESIDENTIAL QUARTER, FENGTAI DISTRICT, BEIJING TO: 515041 NO. 13, YUJIN SOUTH ROAD, ZHUJIN INDUSTRIAL ZONE, SHANTOU CITY, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110510 Address after: 515041 Guangdong city in Shantou Province, the Pearl River Tianjin Industrial Zone, Road No. 13 Co-patentee after: Xu Rongxiang Patentee after: SHANTOU MEBO PHARMACEUTICALS CO., LTD. Address before: 100075 Beijing Fengtai District city Fangzhuang District Fangguyuan District 21 building 401 room Patentee before: Xu Rongxiang |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161024 Address after: 515041 Guangdong city in Shantou Province, the Pearl River Tianjin Industrial Zone, Road No. 13 Patentee after: SHANTOU MEBO PHARMACEUTICALS CO., LTD. Patentee after: Xu Peng Address before: 515041 Guangdong city in Shantou Province, the Pearl River Tianjin Industrial Zone, Road No. 13 Patentee before: SHANTOU MEBO PHARMACEUTICALS CO., LTD. Patentee before: Xu Rongxiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180619 Address after: 515041 No. 13, Yu Jin Nan Road, Zhujin Industrial Zone, Shantou, Guangdong Co-patentee after: Li Li Patentee after: SHANTOU MEBO PHARMACEUTICALS CO., LTD. Address before: 515041 No. 13, Yu Jin Nan Road, Zhujin Industrial Zone, Shantou, Guangdong Co-patentee before: Xu Peng Patentee before: SHANTOU MEBO PHARMACEUTICALS CO., LTD. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20090701 |